From August 2012 to November 2012, the Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, completed surgery on 31 patients with domestic rechargeable brain pacemakers. Patients were divided into a test group (n=15) and a control group (n=16) according to the randomization principle, and the test group was switched on 1 month after surgery and stimulated by adjusting stimulation parameters such as pulse width, frequency and voltage, while the control group was simulated to be switched on but not stimulated, and was unblinded 3 months after surgery to compare the motor scores, daily living ability scores of the Parkinson’s Disease Rating Scale (UPDRS) in the on and off periods and the time without anomalies in the on period between the two groups After unblinding, the control group was switched on and stimulated until 6 months postoperatively and evaluated again. Pacemaker temperature changes, charging capacity and charging stability during charging were also examined. Symptoms gradually improved after the test group was switched on at 1 month postoperatively. Before unblinding at 3 months postoperatively, the UPDRS motor scores, daily living ability scores, and time without aberrations during the off and on phases were significantly improved in the test group compared with the control group and baseline (P<0.05< span="">), while there was no significant difference in the control group compared with baseline (P>0.05); the symptoms gradually improved after the control group was turned on, and the efficacy of the control group gradually converged with that of the test group at 6 months postoperatively. The efficacy was significantly improved compared with baseline (P<0.05< span="">). The domestic rechargeable pacemaker significantly improved UPDRS motor scores and daily living ability scores in PD patients in the open and closed phases, prolonged the anisotropy-free time in the open phase, and reduced the levodopa equivalent dose, which can be used for the surgical treatment of PD.